We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi has announced that it will invest $476 million in a multi-vaccine manufacturing facility in Singapore to mass produce vaccines for the Asian market. Read More
In a much-needed development, Johnson & Johnson began delivery of its one-shot COVID-19 vaccine within the EU yesterday as the trade bloc continues to clamor for enough doses to inoculate its 446 million residents. Read More
Biogen and Chinese drugmaker Bio-Thera Solutions have teamed to develop a biosimilar of Roche’s Actemra (tocilizumab), BAT1806, currently being evaluated in phase 3 trials for moderate-to-severe rheumatoid arthritis. Read More
Cidara will get $27 million upfront as part of the deal with Johnson & Johnson and is eligible for up to $753 million in additional payments. Read More
Under the expanded deal, Catalent is dedicating a new high-speed filling line at its Bloomington site to vaccine production starting next month. Read More
Novartis has entered into a licensing and development agreement with Cambridge, UK-based Artios Pharma to develop new precision oncology drugs. Read More
Moderna has expanded its existing agreement with Catalent to boost COVID-19 vaccine production at Catalent’s fill-and-finish facility in Bloomington, Ind., to supply the U.S. market. Read More
The U.S. government has stepped in to address a serious manufacturing error at Emergent BioSolutions’ Baltimore, Md., facility that wasted 15 million Johnson & Johnson (J&J) vaccine doses. However, putting J&J in charge of the site and barring production of AstraZeneca (AZ)’s vaccine there isn’t likely to halt AZ’s production schedule, a White House official said Monday. Read More